1. Home
  2. UTHR vs NWSA Comparison

UTHR vs NWSA Comparison

Compare UTHR & NWSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • NWSA
  • Stock Information
  • Founded
  • UTHR 1996
  • NWSA 2012
  • Country
  • UTHR United States
  • NWSA United States
  • Employees
  • UTHR N/A
  • NWSA N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • NWSA Newspapers/Magazines
  • Sector
  • UTHR Health Care
  • NWSA Consumer Discretionary
  • Exchange
  • UTHR Nasdaq
  • NWSA Nasdaq
  • Market Cap
  • UTHR 14.4B
  • NWSA 15.7B
  • IPO Year
  • UTHR 1999
  • NWSA N/A
  • Fundamental
  • Price
  • UTHR $287.35
  • NWSA $29.44
  • Analyst Decision
  • UTHR Buy
  • NWSA Strong Buy
  • Analyst Count
  • UTHR 13
  • NWSA 6
  • Target Price
  • UTHR $386.15
  • NWSA $38.80
  • AVG Volume (30 Days)
  • UTHR 721.5K
  • NWSA 3.6M
  • Earning Date
  • UTHR 07-30-2025
  • NWSA 08-07-2025
  • Dividend Yield
  • UTHR N/A
  • NWSA 0.67%
  • EPS Growth
  • UTHR 18.86
  • NWSA 136.22
  • EPS
  • UTHR 25.10
  • NWSA 0.85
  • Revenue
  • UTHR $2,994,100,000.00
  • NWSA $10,268,000,000.00
  • Revenue This Year
  • UTHR $14.30
  • NWSA N/A
  • Revenue Next Year
  • UTHR $6.32
  • NWSA $1.91
  • P/E Ratio
  • UTHR $11.50
  • NWSA $34.73
  • Revenue Growth
  • UTHR 19.84
  • NWSA 19.49
  • 52 Week Low
  • UTHR $266.98
  • NWSA $23.38
  • 52 Week High
  • UTHR $417.82
  • NWSA $30.69
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 42.85
  • NWSA 69.33
  • Support Level
  • UTHR $282.42
  • NWSA $27.25
  • Resistance Level
  • UTHR $293.77
  • NWSA $28.09
  • Average True Range (ATR)
  • UTHR 8.88
  • NWSA 0.47
  • MACD
  • UTHR -0.89
  • NWSA 0.16
  • Stochastic Oscillator
  • UTHR 67.51
  • NWSA 94.05

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About NWSA News Corporation

News Corporation is a diversified media conglomerate with significant presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

Share on Social Networks: